Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
Open Access
Abstract
Emerging viral diseases, including seasonal illnesses and pandemics, pose significant global public health risks. Respiratory viruses, particularly coronaviruses and influenza viruses, are associated with high morbidity and mortality, imposing substantial socioeconomic burdens. This review focuses on the current landscape of respiratory viruses, particularly influenza and SARS-CoV-2, and their antiviral treatments. It also discusses the potential for pandemics and the development of new antiviral vaccines and therapies, drawing lessons from past outbreaks to inform future strategies for managing viral threats.Keywords
Funding Information
- Korea Technology and Information Promotion Agency for SMEs (S3302176, HI22C0607)
- Korea Health Industry Development Institute (KHIDI) (S3302176, HI22C0607)
- SUNJE Co., Ltd. (SUNJAE-PNU Industry-Academic Cooperation) (S3302176, HI22C0607)
This publication has 256 references indexed in Scilit:
- FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral TreatmentJAMA, 2023
- An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccinesJournal of Clinical Laboratory Analysis, 2022
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsJAMA, 2021
- A brief review of influenza virus infectionJournal of Medical Virology, 2021
- An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19JAMA, 2021
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- Tackling COVID‐19 Using Remdesivir and Favipiravir as Therapeutic OptionsChemBioChem, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Understanding of COVID‐19 based on current evidenceJournal of Medical Virology, 2020
- Development Times and Approval Success Rates for Drugs to Treat Infectious DiseasesClinical Pharmacology & Therapeutics, 2019